Back

Key takeaways: addressing residual cardiovascular risk with proven therapies

3 April 2025 (15:50 - 15:55)
Organised by: Logo
Congress Presentation Part of: From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management Secondary Prevention Open Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Professor Gaetano Maria De Ferrari

University of Turin, Turin (Italy)

4 More presentations in this session

Presentation thumbnail
Clinical Case Introduction
Professor V. Aboyans (Monaco, MC)
Slides Video
Presentation thumbnail
U-Prevent: a personalized approach to cardiovascular risk management
Doctor J. Dorresteijn (Utrecht, NL)
Slides
Presentation thumbnail
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
Doctor H. Contractor (Manchester, GB)
Slides Video
Presentation thumbnail
Q&A
Slides

Access the full session

Session thumbnail
From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management
Video

The Event

Event poster

ESC Preventive Cardiology 2025

3 April 2025 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Managing a patient with residual risk: applying recent evidence with EPA to practice
thumbnail
Congress Session
Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)
thumbnail
Congress Session
Addressing residual cardiovascular risk: from evidence to experience

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources